Kuldeep Neote<\/p>\n\n\n\n
MONTREAL, March 24, 2023 \u2013 <\/strong>CQDM is proud to announce the appointment of Kuldeep Neote as a member of its Scientific Advisory Board (SAB). The SAB is a key committee of CQDM as it provides strategic orientations in biopharmaceutical innovation and oversees the selection and monitoring of projects funded by CQDM.<\/p>\n\n\n\n Kuldeep Neote is an Entrepreneur-in-Residence at the National Institutes of Health and at FACIT\/OICR, an investment firm focused on accelerating the commercialization of oncology innovations and located in Toronto. Kuldeep is a molecular biologist by training and has many years of experience in drug discovery in the areas of immunology, inflammation and oncology. Among other things, he has established a drug discovery platform for chemokine receptors, which has led to the discovery and development of several clinical candidates. In recent years, Kuldeep has worked as an advisor to identify scientifically innovative and commercially viable candidates for partnership or investment. His rich and impressive track record in various pharmaceutical companies and his long-standing interest in integrating cutting-edge scientific discoveries into drug discovery programs, gives him a unique expertise that will be a major asset to the SAB and CQDM.<\/p>\n\n\n\n \u201cThe appointment of a biopharmaceutical development expert like Kuldeep Neote to CQDM\u2019s SAB is excellent news. Kuldeep will reinforce the SAB strategic advantage because of his extensive experience in implementing cutting-edge scientific discoveries into drug discovery programs within various biopharmaceutical companies,\u201d said Diane Gosselin, President and CEO of CQDM.<\/p>\n\n\n\n \u201cI am delighted to welcome Kuldeep Neote to CQDM’s SAB. Kuldeep’s broad pharma experience, his knowledge of the Canadian biotechnology landscape and his passion for promoting commercialization of quality basic science will be a great addition to our SAB team,\u201d said Brian Underdown, chairman of CQDM\u2019s SAB.<\/p>\n\n\n\n CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-leading pharmaceutical organizations, Canadian biotech companies, the best researchers from the public and private sectors, as well as the Canadian and Quebec governments. CQDM\u2019s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. For more information please visit: www.cqdm.org<\/a>, and the CQDM\u2019s pages on LinkedIn et Twitter.<\/p>\n\n\n\nAbout CQDM<\/h4>\n\n\n\n